That’s a great point. I know it’s been said before that it would be tricky to sell Zantrene for individual uses.
However, if RAC were able to create a combo between an anthracycline and Zantrene and sell it as a single drug or with a caveat that Zantrene is only used in that combo then there could be potential to sell Zantrene separately as an FTO inhibitor.
All speculation obviously and happy to be proven wrong by Dr T or anyone else.
The “too good to be true” story keeps growing.
Ann: AGM Presentations, page-38
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.000(0.00%) |
Mkt cap ! $289.7M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.70 | $1.65 | $100.0K | 59.95K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 601 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 4823 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |